{"id":"NCT00241839","sponsor":"University of Florida","briefTitle":"Uric Acid and Hypertension in African Americans","officialTitle":"Uric Acid and Hypertension in African Americans","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2005-10-19","resultsPosted":"2013-07-17","lastUpdate":"2013-07-26"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension"],"interventions":[{"type":"DRUG","name":"Allopurinol","otherNames":["Zyloprim"]},{"type":"DRUG","name":"Placebo","otherNames":["sugar pill"]},{"type":"DRUG","name":"Chlorthalidone","otherNames":[]},{"type":"DRUG","name":"Potassium chloride","otherNames":[]}],"arms":[{"label":"A","type":"ACTIVE_COMPARATOR"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pressure (BP) control in African Americans.","primaryOutcome":{"measure":"Change in Diastolic Blood Pressure by Cuff 8-10 Weeks Minus Baseline","timeFrame":"Measured at 8-10 weeks on allopurinol / placebo","effectByArm":[{"arm":"A (Allopurinol)","deltaMin":3.44,"sd":12.25},{"arm":"B (Placebo)","deltaMin":-0.83,"sd":10.63}],"pValues":[{"comp":"OG000 vs OG001","p":"0.059"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["17921363","20871636","16598194","17928827","17855639","19081307","19520625","21849262"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":71},"commonTop":["Headache","Cold","Musculoskeletal pain/ache"]}}